Immune correlates for dengue vaccine development

References

• Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013 Apr 25;496(7446):504–507.
   PubMed Web of Science ®Google Scholar
• Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg. 1952;1:30–50.
   PubMedGoogle Scholar
• Halstead SB. Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med. 1970;42:350–362.
   PubMed Web of Science ®Google Scholar
• Guzman MG, Harris E. Dengue. Lancet. 2015;385(9966):453–465.
   PubMed Web of Science ®Google Scholar
• Rainwater-Lovett K, Rodriguez-Barraquer I, Cummings DA, et al. Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis. BMC Infect Dis. 2012;12:233.
   PubMed Web of Science ®Google Scholar
• Salje H, Rodriguez-Barraquer I, Rainwater-Lovett K, et al. Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development. PLoS Negl Trop Dis. 2014;8(6):e2952.
   PubMed Web of Science ®Google Scholar
• Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med. 1970;42:311–328.
   PubMed Web of Science ®Google Scholar
• Burke DS, Nisalak A, Johnson DE, et al. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg. 1988;38(1):172–180.
   PubMed Web of Science ®Google Scholar
• Montoya M, Gresh L, Mercado JC, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis. 2013;7(8):e2357.
   PubMed Web of Science ®Google Scholar
• Anderson KB, Gibbons RV, Cummings DA, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis. 2014 Feb 1;209(3):360–368.
   PubMed Web of Science ®Google Scholar
• Salje H, Lessler J, Endy TP, et al. Revealing the microscale spatial signature of dengue transmission and immunity in an urban population. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9535–9538.
   PubMed Web of Science ®Google Scholar
• Reich NG, Shrestha S, King AA, et al. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc, Interface/R Soc. 2013 Sep 6;10(86):20130414.
   PubMed Web of Science ®Google Scholar
• Kliks SC, Nimmannitya S, Nisalak A, et al. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg. 1988;38(2):411–419.
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Lei HY, Nguyen TL, et al. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis. 2004 Jan 15;189(2):221–232.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Immune enhancement of viral infection. Prog Allergy. 1982;31:301–364.
   PubMedGoogle Scholar
• Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013 Jul;158(7):1445–1459.
   PubMed Web of Science ®Google Scholar
• Endy TP, Nisalak A, Chunsuttitwat S, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis. 2004 Mar 15;189(6):990–1000.
   PubMed Web of Science ®Google Scholar
• Buddhari D, Aldstadt J, Endy TP, et al. Dengue virus neutralizing antibody levels associated with protection from infection in Thai cluster studies. PLoS Negl Trop Dis. 2014 Oct;8(10):e3230.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Katzelnick L, Tissera H, et al. Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort. J Infect Dis. 2015 Feb 15;211(4):590–599.
   PubMed Web of Science ®Google Scholar
• Mangada MM, Endy TP, Nisalak A, et al. Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J Infect Dis. 2002 Jun 15;185(12):1697–1703.
   PubMed Web of Science ®Google Scholar
• Hatch S, Endy TP, Thomas S, et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis. 2011 May 1;203(9):1282–1291.
   PubMed Web of Science ®Google Scholar
• Gibbons RV, Kalanarooj S, Jarman RG, et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg. 2007;77(5):910–913.
   PubMed Web of Science ®Google Scholar
• Olkowski S, Forshey BM, Morrison AC, et al. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis. 2013;208(6):1026–1033.
   PubMed Web of Science ®Google Scholar
• Tsai WY, Durbin A, Tsai JJ, et al. Complexity of neutralizing antibodies against multiple dengue virus serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies. J Virol. 2015 Jul;89(14):7348–7362.
   PubMed Web of Science ®Google Scholar
• Guy B, Barrere B, Malinowski C, et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011 Sep 23;29(42):7229–7241.
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380(9853):1559–1567.
   Google Scholar
• Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014 Oct 11;384(9951):1358–1365.
   PubMed Web of Science ®Google Scholar
• Villar L, Dayan GH, Arredondo-Garcia JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015 Jan 8;372(2):113–123.
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195–1206.
   Google Scholar
• Osorio JE, Huang CY, Kinney RM, et al. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine. 2011 Sep 23;29(42):7251–7260.
   PubMed Web of Science ®Google Scholar
• Durbin AP, Kirkpatrick BD, Pierce KK, et al. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine. 2011 Sep 23;29(42):7242–7250.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick BD, Durbin AP, Pierce KK, et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis. 2015 Sep 1;212(5):702–710.
   PubMed Web of Science ®Google Scholar
• Govindarajan D, Meschino S, Guan L, et al. Preclinical development of a dengue tetravalent recombinant subunit vaccine: immunogenicity and protective efficacy in nonhuman primates. Vaccine. 2015 Aug 7;33(33):4105–4116.
   PubMed Web of Science ®Google Scholar
• Beckett CG, Tjaden J, Burgess T, et al. Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial. Vaccine. 2011 Jan 29;29(5):960–968.
   PubMed Web of Science ®Google Scholar
• Martinez LJ, Lin L, Blaylock JM, et al. safety and immunogenicity of a dengue virus serotype-1 purified-inactivated vaccine: results of a phase 1 clinical trial. Am J Trop Med Hyg. 2015 Sep 2;93(3):454–460.
   PubMed Web of Science ®Google Scholar
• Schwartz LM, Halloran ME, Durbin AP, et al. The dengue vaccine pipeline: implications for the future of dengue control. Vaccine. 2015 Jun 26;33(29):3293–3298.
   PubMed Web of Science ®Google Scholar
• Dorigatti I, Aguas R, Donnelly CA, et al. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia. Vaccine. 2015 Jul 17;33(31):3746–3751.
   PubMed Web of Science ®Google Scholar
• Lai CY, Tsai WY, Lin SR, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol. 2008;82(13):6631–6643.
   PubMed Web of Science ®Google Scholar
• Churdboonchart V, Bhamarapravati N, Peampramprecha S, et al. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am J Trop Med Hyg. 1991;44(5):481–493.
   PubMed Web of Science ®Google Scholar
• Valdes K, Alvarez M, Pupo M, et al. Human dengue antibodies against structural and nonstructural proteins. Clin Diagn Lab Immunol. 2000;7(5):856–857.
   PubMedGoogle Scholar
• Kuhn RJ, Zhang W, Rossmann MG, et al. Structure of dengue virus. Implications for flavivirus organization, maturation, and fusion. Cell. 2002;108(5):717–725.
   PubMed Web of Science ®Google Scholar
• Allison SL, Schalich J, Stiasny K, et al. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol. 2001;75(9):4268–4275.
   PubMed Web of Science ®Google Scholar
• Gubler D, Kuno G, Markoff L. Flavivirus, field’s virology. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2007.
   Google Scholar
• Hung JJ, Hsieh MT, Young MJ, et al. An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol. 2004;78(1):378–388.
   PubMed Web of Science ®Google Scholar
• Zhang X, Ge P, Yu X, et al. Cryo-EM structure of the mature dengue virus at 3.5-A resolution. Nat Struct Mol Biol. 2013;20(1):105–110.
   PubMed Web of Science ®Google Scholar
• Klein DE, Choi JL, Harrison SC. Structure of a dengue virus envelope protein late-stage fusion intermediate. J Virol. 2013 Feb;87(4):2287–2293.
   PubMed Web of Science ®Google Scholar
• Heinz FX, Stiasny K, Allison SL. The entry machinery of flaviviruses. Arch Virol Suppl. 2004;18:133–137.
   PubMedGoogle Scholar
• Li L, Lok SM, Yu IM, et al. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science. 2008 Mar 28;319(5871):1830–1834.
   PubMed Web of Science ®Google Scholar
• Yu IM, Zhang W, Holdaway HA, et al. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science. 2008 Mar 28;319(5871):1834–1837.
   PubMed Web of Science ®Google Scholar
• Junjhon J, Lausumpao M, Supasa S, et al. Differential modulation of prM cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfurin consensus positions of the dengue virus pr-M junction. J Virol. 2008;82(21):10776–10791.
   PubMed Web of Science ®Google Scholar
• Plevka P, Battisti AJ, Junjhon J, et al. Maturation of flaviviruses starts from one or more icosahedrally independent nucleation centres. EMBO Reports. 2011;12(6):602–606.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010 May 7;328(5979):745–748.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Wongwiwat W, Supasa S, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015 Feb;16(2):170–177.
   PubMed Web of Science ®Google Scholar
• Beltramello M, Williams KL, Simmons CP, et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010 Sep 16;8(3):271–283.
   PubMed Web of Science ®Google Scholar
• Sukupolvi-Petty S, Austin SK, Purtha WE, et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol. 2007;81(23):12816–12826.
   PubMed Web of Science ®Google Scholar
• Lok SM, Kostyuchenko V, Nybakken GE, et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol. 2008;15(3):312–317.
   PubMed Web of Science ®Google Scholar
• de Alwis R, Smith SA, Olivarez NP, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA. 2012 May 8;109(19):7439–7444.
   PubMed Web of Science ®Google Scholar
• Teoh EP, Kukkaro P, Teo EW, et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med. 2012 Jun 20;4(139):139ra83.
   PubMed Web of Science ®Google Scholar
• Fibriansah G, Tan JL, Smith SA, et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun. 2015;6:6341.
   PubMed Web of Science ®Google Scholar
• Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature. 2015 Apr 2;520(7545):109–113.
   PubMed Web of Science ®Google Scholar
• Rodenhuis-Zybert IA, da Silva Voorham JM, Torres S, et al. Antibodies against immature virions are not a discriminating factor for dengue disease severity. PLoS Negl Trop Dis. 2015;9(3):e0003564.
   Web of Science ®Google Scholar
• Puttikhunt C, Prommool T, Nathaporn U, et al. The development of a novel serotyping-NS1-ELISA to identify serotypes of dengue virus. J Clinical Virology: Official Publication Pan Am Soc Clin Virol. 2011;50(4):314–319.
   PubMed Web of Science ®Google Scholar
• Avirutnan P, Fuchs A, Hauhart RE, et al. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med. 2010 Apr 12;207(4):793–806.
   PubMed Web of Science ®Google Scholar
• Avirutnan P, Punyadee N, Noisakran S, et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis. 2006 Apr 15;193(8):1078–1088.
   PubMed Web of Science ®Google Scholar
• Avirutnan P, Zhang L, Punyadee N, et al. Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. Plos Pathogens. 2007;3(11):e183.
   PubMed Web of Science ®Google Scholar
• Beatty PR, Puerta-Guardo H, Killingbeck SS, et al. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci Transl Med. 2015 Sep 9;7(304):304ra141.
   PubMed Web of Science ®Google Scholar
• Costa SM, Paes MV, Barreto DF, et al. Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence. Vaccine. 2006 Jan 12;24(2):195–205.
   PubMed Web of Science ®Google Scholar
• Wu SF, Liao CL, Lin YL, et al. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine. 2003 Sep 8;21(25–26):3919–3929.
   PubMed Web of Science ®Google Scholar
• Gromowski GD, Barrett AD. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology. 2007;366(2):349–360.
   PubMed Web of Science ®Google Scholar
• Fibriansah G, Ibarra KD, Ng TS, et al. DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science. 2015 Jul 3;349(6243):88–91.
   PubMed Web of Science ®Google Scholar
• Sissons JG, Oldstone MB. Antibody-mediated destruction of virus-infected cells. Adv Immunol. 1980;29:209–260.
   PubMedGoogle Scholar
• Kuhn RJ, Dowd KA, Beth Post C, et al. Shake, rattle, and roll: impact of the dynamics of flavivirus particles on their interactions with the host. Virology. 2015 May;479–480:508–517.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Dengue. Lancet. 2007;370(9599):1644–1652.
   PubMed Web of Science ®Google Scholar
• Green S, Pichyangkul S, Vaughn DW, et al. Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J Infect Dis. 1999;180(5):1429–1435.
   PubMed Web of Science ®Google Scholar
• Mongkolsapaya J, Dejnirattisai W, Xu XN, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med. 2003 Jul;9(7):921–927.
   PubMed Web of Science ®Google Scholar
• Dung NT, Duyen HT, Thuy NT, et al. Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue. J Immunology. 2010 Jun 15;184(12):7281–7287.
   PubMed Web of Science ®Google Scholar
• Friberg H, Bashyam H, Toyosaki-Maeda T, et al. Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans. Sci Rep. 2011;1:51.
   PubMed Web of Science ®Google Scholar
• Friberg H, Burns L, Woda M, et al. Memory CD8+ T cells from naturally acquired primary dengue virus infection are highly cross-reactive. Immunol Cell Biol. 2011;89(1):122–129.
   PubMed Web of Science ®Google Scholar
• Stephens HA. HLA and other gene associations with dengue disease severity. Curr Top Microbiol Immunol. 2010;338:99–114.
   PubMed Web of Science ®Google Scholar
• Loke H, Bethell D, Phuong CX, et al. Susceptibility to dengue hemorrhagic fever in Vietnam: evidence of an association with variation in the vitamin d receptor and Fc gamma receptor IIa genes. Am J Trop Med Hyg. 2002;67(1):102–106.
   PubMed Web of Science ®Google Scholar
• Fernandez-Mestre MT, Gendzekhadze K, Rivas-Vetencourt P, et al. TNF-alpha-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. Tissue Antigens. 2004;64(4):469–472.
   PubMed Web of Science ®Google Scholar
• Noecker CA, Amaya-Larios IY, Galeana-Hernandez M, et al. Contrasting associations of polymorphisms in FcgammaRIIa and DC-SIGN with the clinical presentation of dengue infection in a Mexican population. Acta Tropica. 2014 Oct;138:15–22.
   PubMed Web of Science ®Google Scholar
• Mongkolsapaya J, Duangchinda T, Dejnirattisai W, et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J Immunology. 2006 Mar 15;176(6):3821–3829.
   PubMed Web of Science ®Google Scholar
• Ribeiro E, Kassab S, Pistone T, et al. Primary dengue fever associated with hemophagocytic syndrome: a report of three imported cases, Bordeaux, France. Intern Medicine. 2014;53(8):899–902.
   PubMed Web of Science ®Google Scholar
• Tan LH, Lum LC, Omar SF, et al. Hemophagocytosis in dengue: comprehensive report of six cases. J Clinical Virology: Official Publication Pan Am Soc Clin Virol. 2012;55(1):79–82.
   PubMed Web of Science ®Google Scholar
• Lin L, Finak G, Ushey K, et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol. 2015;33(6):610–616.
   PubMed Web of Science ®Google Scholar
• Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009;10(1):116–125.
   PubMed Web of Science ®Google Scholar
• Thomas SJ. Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development. Hum Vaccin Immunother. 2013 Jul;9(7):1587–1590.
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis. 2012 Jun;54(11):1615–1617.
   PubMed Web of Science ®Google Scholar
• O’Connell RJ, Excler JL. HIV vaccine efficacy and immune correlates of risk. Current HIV Research. 2013 Sep;11(6):450–463.
   PubMed Web of Science ®Google Scholar
• Nakaya HI, Wrammert J, Lee EK, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol. 2011;12(8):786–795.
   PubMed Web of Science ®Google Scholar
• Li S, Rouphael N, Duraisingham S, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol. 2014 Feb;15(2):195–204.
   PubMed Web of Science ®Google Scholar
• Tsang JS. Utilizing population variation, vaccination, and systems biology to study human immunology. Trends Immunol. 2015 Aug;36(8):479–493.
   PubMed Web of Science ®Google Scholar